147
Participants
Start Date
November 20, 2020
Primary Completion Date
September 9, 2025
Study Completion Date
September 9, 2025
JNJ-75348780
Participants will receive JNJ-75348780 by subcutaneous (SC) administration.
Austin Hospital, Heidelberg
Linear Clinical Research Ltd, Nedlands
Hosp. Univ. Germans Trias I Pujol, Barcelona
Icahn School of Medicine at Mount Sinai, New York
National Taiwan University Hospital, Taipei
Hosp Univ Fund Jimenez Diaz, Madrid
Clinica Univ. de Navarra, Pamplona
Rambam Medical Center, Haifa
Carmel Medical Center, Haifa
University of Alabama at Birmingham, Birmingham
Hosp Clinico Univ de Salamanca, Salamanca
China Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
CHU Nantes, Nantes
CHRU de Lille Hopital Claude Huriez, Lille
Centre hospitalier Lyon-Sud, Pierre-Bénite
National Cheng Kung University Hospital, Tainan City
Sheba Medical Center, Ramat Gan
The University of Texas MD Anderson Cancer Center, Houston
Chang-Gung Memorial Hospital, Kaohsiung, Kaohsiung City
Tel Aviv Sourasky MC, Tel Aviv
Hadassah Medical Center, Jerusalem
Seoul National University Hospital, Seoul
Severance Hospital Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
The Catholic University of Korea Seoul St Marys Hospital, Seoul
Hospital de Vall D'Hebron, Barcelona
Leicester Royal Infirmary, Leicester
Kings College Hospital, London
The Christie Nhs Foundation Trust, Manchester
Plymouth Hospital NHS Trust, Plymouth
Janssen Research & Development, LLC
INDUSTRY